Lutetium (177Lu) oxodotreotide
The GEPNETs Hunter
Indication: LUTATHERA® is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEPNETs) in adults.
82% risk reduction of progression or death
Established in phases 1, 2 & 3
QUALITY OF LIFE
Improved or maintained versus baseline